Eli Lilly (LLY)
1,417.54
+43.84 (3.19%)
NYSE · Last Trade: Oct 30th, 4:35 PM EDT
News & Press Releases
OmniAb (OABI) Q3 2026 Earnings Call Transcriptfool.com
Revenue jumped to $4M as xPloration expands and Lilly partnership unlocks $3B in milestones.
Via The Motley Fool · October 30, 2026
Eli Lilly Is Now Worth as Much as Warren Buffett's Berkshire Hathaway. Can the Rally Keep Going?fool.com
Eli Lilly's business is heavily driven by one product, while Berkshire Hathaway is a diversified conglomerate.
Via The Motley Fool · October 30, 2026
Can GLP-1s Fatten Your Portfolio? We Examine the VanEck Pharmaceutical ETF vs State Street SPDR Pharmaceuticals ETFfool.com
VanEck's concentrated 26-stock portfolio delivered stronger five-year returns and lower volatility, while State Street's 62-holding fund offers broader diversification and lower fees.
Via The Motley Fool · October 30, 2026
Eli Lilly (NYSE:LLY) Beats Q3 Estimates, Raises Guidance as Shares Jumpchartmill.com
Via Chartmill · October 29, 2026
Novo Has Big Plans for 2030. Should You Buy the Stock Now?fool.com
The company’s comeback strategy looks sound.
Via The Motley Fool · October 29, 2026
Eli Lilly (LLY) Q3 2026 Earnings Call Transcriptfool.com
Revenue surged 39% on blockbuster obesity drug demand and strong international growth.
Via The Motley Fool · October 29, 2026
Eli Lilly Sells 53% More at Lower Prices: Rapid Earnings Reactionfool.com
Eli Lilly’s realized prices fell 15%, but a 53% jump in volume pushed revenue up 39% and lifted full-year guidance by $5.5 billion. Here’s why the math works, and what could break it.
Via The Motley Fool · October 29, 2026
S&P 500 Top Movers: Oct. 29, 2026 Gainers and Loserschartmill.com
Via Chartmill · October 29, 2026
S&P 500 Top Movers: Today's US Session Gainers and Loserschartmill.com
Via Chartmill · October 29, 2026
Eli Lilly (LLY) shares skyrocket, what you need to know
What happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 8.1% in the morning session after the company reported third-quarter 2026 ...
Via StockStory · October 29, 2026
S&P 500 Gap Movers: October 29, 2026 Sessionchartmill.com
Via Chartmill · October 29, 2026
The $294 Billion Peptide Boom: Biotech Companies Positioned for the Next Wave of Growth
Breakthroughs in obesity, diabetes, oncology, and targeted therapies are driving fresh interest in peptide-based medicines and the companies developing the next generation of treatments.
By FN Media · Via GlobeNewswire · October 29, 2026
The $294 Billion Peptide Boom: Biotech Companies Positioned for the Next Wave of Growth
EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NYSE:NVO),(NYSE:HIMS),(NYSE:ENHA),(NYSE:LLY) EQNX::TICKER_END
Via FinancialNewsMedia · October 29, 2026
Eli Lilly Blows Past Sales Expectations And Hikes Outlook On Mounjaro, Zepbound Dominanceinvestors.com
Eli Lilly stock jumped early Thursday on a solid third-quarter report on the back of Mounjaro and Zepbound.
Via Investor's Business Daily · October 29, 2026
Eli Lilly (NYSE:LLY) reports upbeat Q3 2026, guides for strong full-year sales
Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q3 2026 results beating Wall Street’s revenue expectations, with revenue up 38.6% year on year to...
Via StockStory · October 29, 2026
Could Revolution Medicines Be a Millionaire-Maker Stock?fool.com
The path for Revolution Medicines to grow an initial investment of $25,000 into $1 million is a daunting one.
Via The Motley Fool · October 29, 2026
Eli Lilly's Next-Gen Obesity Drug Trounces Ozempic In Head-To-Head Testinvestors.com
Eli Lilly's next-generation weight-loss drug, retatrutide, trounced Novo's Ozempic in a head-to-head study.
Via Investor's Business Daily · October 28, 2026
Eli Lilly (LLY) reports earnings tomorrow: what to expect
Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting earnings this Thursday before market hours. Here’s what you need to know. Eli Lilly beat...
Via StockStory · October 27, 2026
$10,000 Invested in Eli Lilly 5 Years Ago Would Be Worth This Much Todayfool.com
The company has made longtime shareholders much richer.
Via The Motley Fool · October 27, 2026
Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalystsmarketbeat.com
MercadoLibre, Novo Nordisk, Tyler Technologies and Summit Therapeutics trade below recent highs, yet each has earnings or catalysts that could shift sentiment.
Via MarketBeat · October 26, 2026
Which Pharmaceutical ETF Is the Better Buy: iShares’ Domestic IHE or VanEck’s Global PPH?fool.com
IHE has outperformed recently by concentrating in U.S. drugmakers. PPH offers global reach and a higher dividend for investors willing to trade some of that momentum for income.
Via The Motley Fool · October 26, 2026
Which Healthcare ETF Is the Better Buy: Fidelity’s FHLC or State Street’s XLV?fool.com
XLV concentrates on 61 large-cap S&P 500 names, while FHLC casts a wider net with 365 holdings across mid and small caps. Both charge 0.08% annually.
Via The Motley Fool · October 26, 2026
Should You Buy Bristol Myers Squibb While It Trades Below 10 Times Forward Earnings?fool.com
Bristol Myers Squibb is facing a sizable patent cliff, but that's not unusual in the pharma sector.
Via The Motley Fool · October 25, 2026
The Nasdaq Just Had Its Worst Day in 4 Months. Here's the Level That Would Signal a Correction, and What History Says Investors Can Do About It.fool.com
Tech stocks are selling off as investors question the payoff of artificial intelligence (AI) infrastructure spending.
Via The Motley Fool · October 24, 2026
2 Growth Stocks to Hold for the Next Decade (Hint: These Aren’t AI Stocks)fool.com
These drugmakers are capitalizing on their pipeline successes.
Via The Motley Fool · October 23, 2026